LabCorp Enhances Genomics Portfolio With Acquisition
By Ed Miseta, Chief Editor, Clinical Leader
LabCorp Clinical Trials, already a leading provider of late-state core genomic services including mutation analysis, pharmacogenetics, and pharmacogenomics, has expanded its offerings with the acquisition of Covance Genomics Laboratory (CGL). The additional offerings will allow LabCorp to meet client needs with a more comprehensive set of services ranging from preclinical/early development all the way through to late stage development.
CGL, located in Seattle, is a provider of complex genomic analysis including gene expression array studies and next generation sequencing applications in support of pharma and biotech drug development. The expertise acquired from CGL is expected to complement and broaden the existing global clinical lab network that LabCorp has in place and will better enable the company to expand its capabilities into the future. Approximately 50 scientists and staff members from CGL will also be joining the LapCorp team.
LabCorp and Covance have also announced they will have signed a five-year services collaboration agreement that will allow Labcorp to continue offering specialty genomic services to Covance clients. Those services include LabCorp’s biomarker development and companion diagnostics capabilities, as well as its translational biomarkers, computational biology, and next generation sequencing genomic services.
Source: